Innovative Peptide Solutions

Custom Peptide Services

Custom & Specialty Peptides Clinical Peptides Peptide Libraries Peptide Pools Peptide Arrays Peptidomimetic & Organic Synthesis

Innovative Peptide Solutions JPT’s key technologies are:

Custom & Specialty Peptides We are peptide experts with a track record of more than 20 years and offer the largest variety of peptide History chemistries, formats and modifications. JPT Peptide Technologies is a service provider located in Berlin, Germany that has achieved worldwide credi- PepMix™ bility for its commitment to rigorous quality standards Defined antigen spanning peptide pools to and a reputation for developing and implementing stimulate CD4+ and CD8+ T-cells. innovative peptide-based services and research tools for various applications. PepTrack™ Together with its US-subsidiary JPT serves its clientele Peptide libraries of individual peptides offering in the pharmaceutical and biotechnology industries as various specifications and optimization for different well as researchers in universities, governmental and types of assays. non-profit organizations. Clinical Peptides Custom peptides produced for the stringent require- ments of cellular therapy as well as vaccine and Technology & drug development.

Application PepStar™ Over the past decade JPT has developed a portfolio of Peptide microarray platform for antibody epitope propietary technologies as well as innovative products dis­covery, monitoring of humoral immune responses, and services that have helped to advance the develop- protein-protein interactions and enzyme profiling. ment of new immunotherapies, proteomics and drug discovery. SPOT High-throughput peptide synthesis for T-cell epitope discovery , neo epitope qualification and peptide lead Quality Assurance discovery.

JPT is DIN EN ISO 9001:2015 certified and GCLP audited. SpikeTides™ Light and stable isotope-labeled or quantified peptides for mass spectrometry based proteomics assays.

SpikeMix™ Stable isotope-labeled peptide (SIL) pools used as peptide standards in mass spectrometry based assays.

4 /PepSpots™ Peptide Arrays on Membranes 1 /Microarray &ELISA Assay Service eptide Arrays &Peptide ELISA 20 PepTrack™ / 2 Libraries Peptide eptide Libraries Peptide & Pools 10 Custom / 4 Peptides ustom & Specialty Peptides 04

/ / /

P

2 2 2 2 2 1 1 1 1 1 0 0 0 C P 4 /PepMix™ Peptide Pools for T-cell Assays 9 / BioTides™ / 9 Small Biotinylated Scale Peptides 8 /SpikeMix™ Peptide Pools &Sets 6 / SpikeTides™ / 6 Peptides Isotope-Labeled 2 / 2 5 / Peptide / 5 ELISA 3 /RepliTope™ Catalog Peptide Microarrays 6 / Specialty Peptides Specialty / 6 8 / Clinical / Peptides8  P epStar™ Customized Microarrays Peptide

1 Custom Peptides Table of Contents Services Choose JPT for all peptide needs!

We are the Peptide Experts! We have 99% Success Rate! We select and optimize our synthesis and purifica- JPT has a substantial track record providing custom pep- tion meth­ods and techniques for every synthesis. tides, peptidomimetics, and proteins to the global scientific Therefore, we have a very high success rate (over community. We produce peptides in a range of purities, at 99%). We go the extra mile to get your peptides different quantities, with and without modifications. done!

Our Service is the Best! Our Quality Controls JPT provides the most comprehensive portfolio We offer quick and personal consultation of state-of-the-art analytical quality control with experienced scientists and help you procedures for peptides such as HPLC-MS, with the selection of peptide specifications, UPLC-HR-MS, MALDI-MS, ESI-TOF-MS, AAA, provide tips for storage, solvents and more. NMR, content determination and many more. Take advantage of our rush order service for urgent projects.

Certified Quality Standards For more than a decade JPT's operations run Proprietary Technologies by JPT un­der a quality management system based on We developed several proprietary technologies that enable a the latest ISO 9001 standards. wide range of applications and uncomparable prices. In addi- We fulfill highest health and environmental stan- tion, we offer the widest product portfolio of peptide-related dards and invite our customers to inspect our products in the market. facilities.

2 Let’s talk about:

Peptide Purity Stability & Storage Even small impurites may create huge prob- Most peptides are stable for years, if stored lems in certain assays. However, the impact of correctly. However, about 20 % of peptides such by-products depends strongly on your have a limited shelf stability! But how do you specific application. Therefore, it is essential recognize and handle potentially unstable­ to choose the appropriate purity level. peptides? We have the tools and the long Tell us about your application to select the term data to do so. best specification for your peptides! Ask us!

Solubility Peptide Content & Net Weight Ever had the problem to dissolve a peptide Peptide purity is measured by HPLC. In addi- or having limited solvent choices? How about tion to side products analyzed by HPLC, pep- using our help to predict the solubility of a tides contain non-peptidic components. The peptide in advance and selecting the peptide quantification of those is essential to accu- sequences that work best? Or let us do a com- rately adjust peptide concentration. plete solubility test to find the best solvent? Ask us to get fast and inexpensive access to Talk to us! the real peptide content.

$ Value Difficult Peptides $ We work hard to meet your budget. Our pat- Most peptides are assembled by automated ented technologies enable cost effective and synthesis and purification. However, many tailored quotes for your specific application! peptides are difficult to isolate due to their unique physicochemical properties. Our goal is to deliver every peptide and we never stop Delivery Time if an initial synthesis fails. We appreciate that your time is precious and Ask us to learn about our strategies for work hard to keep agreed timelines. Any de­lays difficult peptides. will be communicated promptly.

3 Custom Peptides 4 AU (220 nm) Custom & Specialty Peptides Services peptide. each data with analytical the We provide peptides. custom of control Quality Ask for ouraliquotingandvalidated poolingservices! &Pooling Aliquoting SpikeTides™ andPepTrack™. peptide libraries withsmalleramounts, refer to and we are ableto deliver upto several grams. For minimumorderOur for custom peptides is1mg Custom Peptide Scale IncludesOur Service years! 20 than most challenging synthesis projects because we are the peptide for more experts in providing high quality peptides for all applications. We are able to meet the We do not just synthesize peptides. and have JPT its staff considerable knowledge Custom Peptides Peptides &Specialty Custom • • • • •

Competitive prices Competitive techniques state-of-the-art using control quality Reliable protocols and methods synthesis peptide Optimized specifications peptide with Help Consultation with scientists experienced Retention Time(min)

Signal Intensity (%) Custom Peptide Purity Options Custom Peptide Purity tional analyses for custom peptides, e.g. HRMS, HPLC orUPLC andoffer awiderange ofaddi- We provide control quality for eachpeptideby MSor Control Options Quality • • • • • • • • • • • • •

HPLC-MS) HPLC-MS) HPLC-MS) > 95 HPLC-MS) > 90 > 80 > 70 product) main is peptide (target guarantee with unpurified by MS) is detected (peptide unpurified Endotoxin and sterility testing sterility and Endotoxin tests stability and Solubility NMR Peptide content determination analysis acid Amino UPLC-HRMS) HPLC-MS) > 98 > 98

% ( % ( % ( % ( % ( % ( Right: HRMS spectrum of peptide H-LAQLLLILSHIR-OH. H-LAQLLLILSHIR-OH. peptide of UPLC spectrum Left: Mass-to-Charge (m/z) > > > > Selected References Selected “ gG Antibody Responses togp120 Responses Recombinant Antibody gG pro Variation Mechanism the Polymorphic on of ffects tructural Insights into the Intertwined haracterization of RA839, a Non-covalent Small- “ “ “ “ J. Currier, Walter Army Reed Institute, USA Maryland, Rockville, responses. As have the cyclic peptides been from to JPT validate these findings! been very useful for the correlation of the clinical outcome with humoral immune become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT's PepStar™ use infection. JPT's The of protection HIV from Microarray technology has Thai Phase Vaccine I/II Thai Trials Vaccine using Different C I E   S  Nrf2 Signalling” Nrf2 (2015) of Endoplasmic Reticulum Aminopeptidase 1” Regimens” S Dimer of Fyn of SH2” Dimer molecule Binder to Keap1 Binder molecule of Activator Selective and Winkel et al., J Biol Chem. (2015) Chem. JBiol al., et Winkel teins, gp70V1/V2 aCyclicV2 and Scaffolds in Peptide Huculeci et al., Protein Sci. (2015) Protein Sci. al., et Huculeci K tamogiannos et al., Molecular Immunology (2015) Immunology Molecular al., et tamogiannos The RV 144 trial HIV is considered as one of first successful vaccine HIV trials. It has arasavvas et al., AIDS Res Hum Retroviruses. Retroviruses. Hum Res AIDS al., et arasavvas - > > >

hrombin-induced Lysosomal in Human Exocytosis -Secretase Processing APP of Inhibits istone H2AX Y142istone H2AX is a Phosphorylation “ “ “ η ADP and Regulated by Endothelial-derived H Neuronal Activity in the Hippocampus” the in Activity Neuronal T Substances” Low Abundance Modification” Low Abundance Spectrometry (2015) Spectrometry Södergren et al., Platelets (2015) Platelets al., et Södergren Platelets is Dependent on Secondary Activation by Activation Secondary on isPlatelets Dependent Willem et al., Nature (2015) Nature al., et Willem H atimy et al., International Journal of Mass Mass of Journal International atimy al., et ”

5 Custom Peptides Custom & Specialty Peptides Services O OH O O O H H H N N N 2 N N OH

pt id es H H O O

Pe O

es O HO

om NHAc vic st r Se Cu HOHO

Specialty Peptides

We are experts in designing and producing modified peptides, labeled and cyclic peptides as well as other peptide modifications such as various peptide conjugates and peptide esters. We ensure that the most appropriate methods and techniques are selected for every peptide synthesis project. For many years our customers have grown to rely on our exceptional quality and reliability.

Our Service Includes Selected References • Consultation with experienced scientists > “STAT3 in CD8+ T Cells Inhibits Their Tumor • Development of a synthesis strategy by Accumulation by Downregulating CXCR3/ peptide chemists CXCL10 Axis” • Production of building blocks Yue et al., Cancer Immunol. Res. (2015) • We do not give up! Our success rate is > 99 % > “Development and Characterization of Pepducins as Gs-biased Allosteric Agonists” Capabilities Carr et al., J Biol Chem. (2014) • Synthesis of building blocks that are not commercially available > “Characterization of SnO2-Based 68Ge/68Ga • Peptide design and optimization Generators and 68Ga-DOTATATE Preparations: • Extended organic synthesis facilities Radionuclide Purity, Radiochemical Yield and • Solution and solid phase techniques Long-term Constancy” • Conjugation of peptides to shuttle molecules, Sudbrock et al., EJNMMI Research (2014) biologicals, carbohydrates and adjuvants • Stabilizing peptides by: cyclizations, disulfide and thioether bridges, incorporation of structures, Custom & Specialty Peptides Custom & Specialty creation of stapled peptides • Unusual modifications, peptide bond isosters, click chemistries and more

Our research relies heavily on developing robust high-throughput screens with “fluorescent peptides. We have found that JPT's are the best on the market because the signal-to-noise ratio is very high, providing the sensitivity we need for the screens. Their peptides always perform well. In addition, the knowledge, wonderful customer support, and fast turnaround time provided by JPT have been invaluable in us develop the best peptides for our assays. F C. Koehler, UCLA, Los Angeles, CA, USA ” NH NH2 H N O 2 O H O N N H O O N H HN NH N O O 2 O HN NH O O NH N HN SHN NH O 2 O NH HN O O NH 2 O HN O HN NH HO O O O HO O H H NH N N NH2 O N N N HN O O H H H HO O O O OH NH OH O HN O H N N N N 2 NH HO N 6 N O HN H O NH2 CONH2 pt id es Pe es om vic st r Se Cu

Peptide modifications and their common uses

Modification Applications Examples • D-amino acids, homo amino • Increase activity, selectivity and plasma acids, N-methyl-, beta amino Unnatural, stability in drug discovery acids, gamma amino acids Unusual • Induction or stabilization of secondary • Hydroxyproline, beta-alanine, Amino Acids structures e.g. helices, sheets, turns citrulline, ornithine, pyroglu- tamic acid • Acetylation, urea, carbamate, • N-terminal acetylation to imitate the natural sulfonamide, alkylamine N-Terminal structure in a protein • Radioligands like DOTA, Modifications • Stabilization towards enzymatic degradation NOTA, NODAGA by exopeptidases • Dyes and quenchers • Methylation at arginine or • Study of transcription, cell division, apopto- lysine sis, signal transduction, cell adhesion, cell • Lys(GG) (PTMs) Post- growth, infection, immunological differentia- • Phosphorylation and translational tion, bacterial proteins phosphate analogs Modifications • Cys modifications for various applications • Glycosylation e.g. proteomics experiments • Pam3Cys, sulfonic acid • Methionine sulfoxide Internally • Free of fluorescent impurities Quenched / • Enzymatic assays • Large variety available, e.g. FRET • FRET experiments Abz/ Dnp, Mca/ Dnp, EDANS/ Peptides Dabcyl, FAM/ Dabcyl • Head-to-tail cyclization • Mimicry of secondary structures Cyclic • Side-chain-to-side-chain

• Optimization of peptides (increased binding Peptides Custom & Specialty Peptides • Head-to-side-chain potency, selectivity, protease stability) • Side-chain-to-tail cyclization • Heavy lysine (U-13C6; Isotope- • See SpikeTides™ (> p. 16) and U-15N2) Labeled SpikeMix™ (> p. 18) • Heavy arginine (U-13C6; Peptides U-15N4) • C-t erminal amide to imitate part of a • A cid, amide, ester, aldehyde, C-Terminal parental protein sequence pNA, Amc, hydrazide, CMK, Modifications • No additional charges in the peptide biotin, labels and dyes

Fluorescent • Examples: Abz, FITC, FAM, • Protein binding studies Dye Labeled Alexa Fluor, TAMRA, Mca, • Localization experiments Peptides Dylight, Cy3, Cy5 • D etection of tagged peptides (e.g. with • Biotin, desthiobiotin F Biotinylated labeled antibodies) • Flag, Myc, HA tags and Tagged NH • S eparation of tagged peptides from • Tat, oligo arginine tags Peptides O untagged ones • Linkers and spacers O H O N H O N Linker / • B eta-alanine, O1Pen, Ahx, HN • Enhancing stability and bioavailability of NH2 Spacer / O2Oc, Ttds, PEG with various O peptides in vivo NH O O PEGylations lengths N NH2 • Chemoselective dimerization O NH • Increase in affinity (e.g. GPCR ligands) O Peptide methods by formation of O • Increased immune response (MAPs) HN Dimers Cys-maleimide thioethers, HO disulfides or triazoles NH O Protein HN O Conjugates / HO • G eneration of anti-peptide antibodies • KLH, BSA, HSA, OVA Immunogenic NH OH Peptides O HN O H N N N N 2 NH N N O HN 7 H O NH2 CONH2 pt id es Pe es om vic st r Se Cu

Clinical Peptides

Our enhanced production environment for Clinical Peptides & Pools goes beyond ISO 9001:2015 regulations to meet the more stringent product requirements of immunotherapy as well as vaccine and drug development. Thus, the resulting Clinical Grade & ISO Plus Peptides & Pools have been approved for specific clinical trials in the USA and in Germany.

Quality Assurance and Control Why choose JPT? • Vendor qualification • More than 20 years experience on peptides • Incoming material inspection as drugs, vaccines and for cell therapies  • ADCF policy • Comprehensive know-how and dedicated staff • Cleaning validation make us the peptide experts • Full traceability • QC beyond ISO 9001:2015 regulations • QC/QA documentation • Track record of successful clinical peptide projects • Batch release control • Publication record of clinical trials using JPT

Optional Analyses • Chemical analyses acc. to ICH guidelines, e.g. residual solvent and peptide content determination, amino acid analysis, UPLC measurement, stability and solubility testing • Microbiological analyses, e.g. endotoxin and biobur- den determination, sterility testing, bacteriostatic and fungistatic effect Custom & Specialty Peptides Custom & Specialty We recently demonstrated the feasibility and clinical benefit associated with the “infusion of rapidly generated single-culture VSTs, manufactured using JPT’s Clinical Grade PepMix™ Peptide Pools covering 12 immunogenic antigens from five viruses (EBV, AdV, CMV, BK, and HHV6). When administered to 11 allogeneic stem cell trans- plant recipients, 8 of whom had up to four active infections, these VSTs produced an overall 94% response rate. A. M. Leen, Baylor College of Medicine, Houston,” TX, USA

8 pt id es Pe es om vic st r Se Cu

Quality Levels

Specification ISO 9001:2015 RuO ISO 9001:2015 Clinical Grade

Epitope Discovery & T-Cell Expansion & Applications Immune Monitoring DC Pulsing

Incoming Material Inspection x x

Vendor Qualification x x

ADCF Policy x x

Batch Release x x

Certificate of Analysis x x

Document Management x x & LIM-Systems

Cleaning Validation x

Line Clearance x

Delivery in Certified Vials x

Optional Services: Residual Solvents; Sterility, x x Endotoxin; Monitored Storage… Custom & Specialty Peptides Custom & Specialty

Selected References > “  Peptide‐stimulated Expansion of Virus‐specific T cells > “  Expanded Cytotoxic T-cell Lymphocytes Target the for Preventative Treatment After Allogeneic Stem Cell Latent HIV Reservoir” Transplantation” Sung et al., Journal of Infectious Diseases (2015) Gary et al., AppNote (2015) > “  Ex vivo Expansion of Human T cells for Adoptive > “  Activity of Broad-Spectrum T Cells as Treatment for Immunotherapy Using the Novel Xeno-free CTS AdV, EBV, CMV, BKV, and HHV6 Infections After HSCT” Immune Cell Serum Replacement” Papadopoulou et al., Sci Transl Med. (2014) Smith et al., Clinical & Translational Immunology (2015) > “ Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy” Lam et al., Molecular Therapy (2015)

9 pt id es Pe es om vic st r Se Cu

Peptide Libraries & Peptide Pools

JPT is the leading worldwide provider of peptide libraries and pools. We offer a variety of modifications and specifications to comply with all assay formats in applied immunology, proteomics and drug discovery. We produce according to DIN ISO 9001:2015 regulations and in compliance with good clinical laboratory practices (GCLP).

Peptide Library Formats • Peptide purities from crude to > 98 % • Scales from nmols to grams • Number of peptides up to one million • Peptide length variable depending on library platform • Various modifications available (e.g. PTMs, labels, biotin) • Delivery formats (e.g. microtiter plates, tube racks)

Select Your Peptide Platform

Peptide Libraries & Pools Libraries Peptide Peptide Platform Peptide Specification Assay Type

Purified peptides with and without post-translational Cell-Based Assays PepTrack™ modifications (glycosylation, methylation, (ELISPOT, ICS, etc.) phosphorylation, acetylation and more) Premade peptide pools for infectious or tumor anti- T-cell assays (ELISPOT, PepMix™ gens (protein spanning overlapping peptides) Flow cytometry, ICS) Biotinylated peptides (e.g. for immobilization to strep- Binding Assays (Biacore, BioTides™ tavidin coated beads, membranes, microarrays) ILB, Microarrays, etc.)

Enzyme Substrate Sets Peptides containing phosphorylation or cleavage sites Enzymatic Assays

Proteotypic peptides unlabeled or heavy isotope- SpikeTides™ SRM/MRM Assays labeled with or without quantitation Peptides labeled with fluorescence dyes of varying Fluorescence Based PepTrack™ absorption and emission wavelengths Assays High-Throughput Micro-Scale Peptides Large numbers of small scale peptides at low cost Screening Library of biotinylated and non-biotinylated histone Histone Code Peptide Protein-Histone peptides with numerous post-translational modifica- Sets Interaction Studies tions Premade sets and mixes for specfic protein families, SpikeTides™ Sets and e.g. tumor associated antigens, peptide hormones, MRM/SRM Assays SpikeMix™ metabolic enzymes or cytokines Our Peptide Library Discuss your specific requirements with JPT’s peptide Your Assay Requirement Solution experts

JPT’s peptide libraries range from economic small scale libraries consisting of unpurified peptides to specific and complex collections of purified peptides. They vary in amounts, QC/QA measures as well as peptide modifications including phosphorylation, alkylation, glycosylation and many more.

10 pt id es Pe es om vic st r Se Cu

 Selection of JPT’s Peptide Library Types

Overlapping Peptide Scan

An overlapping peptide scan is generated to identify epi­ topes, substrates or other binding sites within a given pro- tein sequence. A free and easy-to-use tool for generation of overlapping peptide sequences can be found on our website (www.jpt.com/support/software).

Lenght: 13 aa Offset: 2 aa Neo Epitope Library

Alanine Scanning Truncation Analysis Analysis NGS results

A A

A M

A W

A Fast assembly and pooling of neo

A epitopes directly from NGS results. & Pools Libraries Peptide A

A

A Positional Scanning A Analysis Each residue is substituted A for an alanine enabling identification of key residues C in your peptide sequence. Truncation of the peptide D sequence from both termini results in identification of the E minimum epitope, substrate F or binding motif. Cyclization Library G H 1 2 3 4 5 6 7 8 9 I 4 5 4 5 The formation of different cycles 3 3 K 2 6 2 6 within the peptide sequence L 1 9 7 7 mimics different loops within the 8 1 8 9 corresponding protein. M

4 5 4 5 4 5 N 6 6 6 3 3 3 P 2 9 7 7 7 8 2 8 2 1 8 1 1 9 9 Q R 3 5 4 5 5 5 2 4 4 4 One or all residues within the 6 6 6 6 S 1 9 2 3 3 3 7 peptide are replaced by all 20 7 8 7 7 8 2 2 1 8 T 1 1 natural amino acids (or modified 9 8 9 9 V ones, analogs and others) to 3 6 7 8 identify motifs within consensus 2 4 9 W 5 5 5 5 8 5 9 sequences. 1 6 6 6 6 7 1 9 3 4 4 4 4 Y 7 2 7 7 2 2 8 8 3 3 3 1 9 2 8 1 1 9

11 pt id es Pe es om vic st r Se Cu

PepTrack™ Peptide Libraries

Our customized peptide libraries offer unlimited flexibility. They are optimized for antigen-specific stimulation of T-cells in immune monitoring, T-cell epitope identification, and development of cellular therapies. We implemented specific parameters for synthesis, purification and analysis of peptide libraries that are important to avoid false positive T-cell responses or toxic inhibition of T-cells and increase shelf-life of peptides.

Specifications Selected References • Tailored peptide libraries > “ Conformational Instability Governed by Disulfide • Different quality grades (see table) Bonds Partitions the Dominant From Subdominant • Optimized for cellular assays Helper T-cell Responses Specific for HIV-1 Envelope • PTMs and labeling available Glycoprotein gp120” • Production ISO 9001:2015 certified Nguyen et al., Vaccine (2015)

> “Mutant MHC Class II Epitopes Drive Therapeutic Immune Responses to Cancer” Kreiter et al., Nature (2015)

> “Identification of Immunodominant CD4-Restricted Epitopes Co-Located with Antibody Binding Sites in Peptide Libraries & Pools Libraries Peptide Individuals Vaccinated with ALVAC-HIV and AIDSVAX B/Edd” Ratto-Kim et al., PLoS One. (2015)

PepTrack™ Peptide Libraries are delivered freeze-dried in multiwell plates or tube racks (micronics).

12 pt id es Pe es om vic st r Se Cu

PepTrack™ Options

Purity QA/QC* Length ** Scale** Delivery Format

Freeze-dried in Fast Track Unpurified 5 % LC-MS 5 -15 aa 50 -100 nmol 96 -well plates LC-MS each Freeze-dried in Research Track Unpurified 7 -15 aa 1-5 mg peptide 96 -tube racks Main product LC-MS each Freeze-dried in Research Track Plus 7 -15 aa 1-5 mg = target peptide peptide 96 -tube racks LC-MS each Freeze-dried in Research Track Plus > 70 % 7 -15 aa 1-5 mg peptide 96 -tube racks LC-MS each Freeze-dried in Trial Track > 80 % 7 -15 aa 1-5 mg peptide 96 -tube racks > 90 % LC-MS each Freeze-dried in Trial Track Plus > 95 % 7 -15 aa 1-5 mg peptide 96 -tube racks > 97 %

* Please inquire for additional QC ** Please inquire for larger amounts and longer peptides

For reliable monitoring of tumor and virus specific T-cell responses we have a & Pools Libraries Peptide “permanent need for peptides and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard which continuously works on improving it's peptide based services. C. Scheibenbogen, Charité Berlin, Berlin,” Germany

Below: Automated synthesis of PepSpots™ membranes.

13 pt id es Pe es om vic st r Se Cu

PepMix™ Peptide Pools for T-cell Assays

JPT's PepMixes™ are synthetic peptide pools containing overlapping peptide scans through antigens or selected MHC restricted epitopes. Each peptide is analyzed to meet the requirements of T-cell assays. Peptides are pooled according to our proprietary validated protocol ensuring presence of all peptides in the pool.

Benefits Selected References For reliable and validated T-cell assays such as ELISPOT, > “ Metabolic Regulation of Hepatitis B Immuno­ appropriate positive and negative controls are ess­en­ pathology by Myeloid-derived Suppressor Cells“ tial to confirm proper functionality of the assay and Pallett et al., Nature Medicine (2015) viability of the cells. Compared to commonly used con- trols like PHA, ConA or full length antigens, synthetic > “ The Tuberculosis Vaccine H4: IC31 is Safe and peptide pools offer the advantage of a high batch-to- Induces a Persistent Polyfunctional CD4 T cell batch reproducibility, application of reliable chemical Response in South African Adults: A Randomized and biochemical QC/QA measures, longer stability and Controlled Trial” ex­tremely efficient immunostimulation. Geldenhuys et al., Vaccine (2015)

> “ Priming with a Simplified Intradermal HIV-1 DNA Applications Vac­cine Regimen followed by Boosting with Re­­­com­­­ Efficient in vitro stimulation of antigen-specific binant HIV-1 MVA Vaccine Is Safe and Immuno­genic: CD4+ and CD8+ T-cells A Phase Iia Randomized Clinical Trial” • For optimization and validation of T-cell assays Munseri et al., PloSOne (2015) Peptide Libraries & Pools Libraries Peptide • For monitoring of cellular immune responses • For vaccine efficacy testing > “ A Phase I Trial Combining Decitabine/dendritic Cell • As positive and negative controls Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 • For T-cell epitope mapping for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma” Krishnadas et al., Cancer Immunol Immunother. Specifications (2015) • Length/Overlap: 15 / 11 aa (for pooled peptide scans) • Purity: 70 % to 95 % (LC-MS) • Amount: 25 tests/vial

Production and use of PepMix™ Peptide Pools. From the antigen prima- ry sequence we create an overlapping peptide scan. The corresponding peptides are synthesized, purified and pooled according to a validated pooling method ensuring presence of all the peptides in the mix. The PepMix™ is then used for T-cell stimulation.

Antigen Sequence ID Overlapping Peptide Scan Pooling & Aliquoting Stimulation of T-cells, e.g. through Antigen Sequences for Immune Monitoring or Cell Therapy

14 pt id es Pe es om vic st r Se Cu

 Select Your PepMix™ Infections AAV BKV Candida CyCMV EBV F. tularensis HAdV HBV HCMV HEV HHV HHV2 HIV Cancer Controls HPV Influenza A L. monocytogenes RLCV Breast Cancer Burkitt's CEF Pool CEF (ext.) Pool RSV VACV VZV YFV Lymphoma Gastric Cancer CEFT Pool EF Pool Zaire ebola virus Genital Cancer Glioma Hodgkin's HCMV (pp65) HCMV (IE1) Zika virus Lymphoma Leukemia Liver Cancer HCMV (IE2) Human Melanoma Merkel Cell Carcinoma (Actin) Human (MOG) Nasopharyngeal Carcinoma Ovarian Cancer Prostate Cancer Testicular Cancer

Customized Matrix Pools PepMix™ Matrix pools offer an efficient We offer fast and low priced way to map epitopes by present- production of tailored PepMixes™ ing each peptide in two different from your specific antigen, neo pools. Have a look at the figure epitopes or peptide library. We below! Our customer support help choosing the appropriate team will assist you with the peptide purity, specifications design.

and pool layout. & Pools Libraries Peptide

A full up-to-date list can be found on: www.shop.jpt.com

[...] we utilised the PepMix™ CEF Pool (extended) as well as a custom synthesized “PepMix™ spanning the core region of HBV genotype D. [...] Our entire experience with JPT, from ordering/delivery to use in the lab was excellent. [...] JPT will remain our “go-to” company for purchasing peptides. L. Pallett, Infection and Immunity, University College London, UK ”

Customized Matrix Pools enable the fast and minimal material Pool No. VIIIVIIVIVIVIIIIII consuming identifcation of the epitope(s) within an antigen. IX 2 Each peptide is present in only two Matrix Pools. In the example X 20 shown, 64 peptides are pooled into 16 Matrix Pools. Pools V and XI 2222220 XIII elicit a T-cell response. Only peptide 37 is present in both pools XII 2022222 and therefore is the peptide containing the epitope. XIII 0 XIV 2 XV 20 XVI 20

Master Pool contains all 64 peptides. Matrix Pool I contains peptides 1, 9, 17, 25, 33, 41, 49 and 57. Matrix Pool II contains peptides 2, 10, 18, 26, 34, 42, 50 and 58. ... Matrix Pool IX contains peptides 1, 2, 3, 4, 5, 6, 7 and 8. Matrix Pool X contains peptides 9, 10, 11, 12, 13, 14, 15 and 16. 15 pt id es Pe es om vic st r Se Cu

SpikeTides™ Isotope-Labeled Peptides

JPT developed a synthesis technology to enable ultra-fast, highly parallel and inexpensive synthesis of small scale isotopically labeled peptides. They are ideally suited for proteome wide profiling using SRM/MRM proteomic assays. In addition, these peptides can be delivered absolutely quantified in a most reliable and economic way.

One approach for quantitative analysis of proteins in Selected References complex mixtures is the use of tandem mass spectro- > “ Needles in the Blue Sea: Sub-Species Specificity in metry to monitor proteotypic peptides by selected Targeted Protein Biomarker Analyses Within the Vast reaction monitoring (SRM) or by parallel analysis of Oceanic Microbial Metaproteome” many proteotypic peptides using multiple reaction Saito et al., Proteomics (2015) mo­nitoring (MRM). For absolute quantitation, stable isotope-labeled proteotypic peptides are used as inter- > “ Targeted Proteomics of Human Metapneumovirus in nal standards. These standards usually need to be puri- Clinical Samples and Viral Cultures” fied to enable subsequent peptide content determina- Foster et al., Analytical Chemistry (2015) tion. This results in prices of several hundred US$ / € per peptide. JPT overcomes this situation by attaching a > “ Biomarker Development for Intraductal Papillary small chemical tag (Quanti-Tag) to the proteotypic pep- Mucinous Neoplasms Using Multiple Reaction tide which allows our specialists cost efficient quantita- Monitoring Mass Spectrometry” tion of the proteotypic peptide. When you digest your Kim et al., J. Proteome Res (2015) sample, spiked with the appropriate SpikeTides™, the Peptide Libraries & Pools Libraries Peptide protease will cleave the peptide-tag bond, releasing > “ Prediction of Colorectal Cancer Diagnosis Based on the desired proteotypic peptide for your measure- Circulating Plasma Proteins” ments. Surinova et al., EMBO Mol Med. (2015)

Quantification of Proteins with JPT's Proteomics Tools. Proteins of interest or whole cell proteome

Tryptic digestion SpikeMix™ Peptide Pools • Customized or o ‐the shelf Proteotypic peptides • Stable isotope‐labeled • PTMs & alkylation • Inexpensive & fast • e.g. TAAs, cytokines and more A) Shotgun experiments or B) SRM/MRM assay setup SpikeTides™ Peptides • Customized • Stable isotope‐labeled or light Identi cation and relative • PTMs & alkylation • Inexpensive & fast quanti cation of proteins

SRM/MRM assay with Quantied SpikeTides™_TQL absolutely quanti ed • Customized or o -the-shelf • Stable isotope‐labeled reference peptide(s) • Absolute quantication • PTMs & alkylation Absolute quanti cation of • Inexpensive & fast proteins of interest 16 pt id es Pe es om vic st r Se Cu

 SpikeTides™ Options

SpikeTides™ – light • Small scale, unpurified, unlabeled proteotypic peptides with C-terminal Arg or Lys for optimization and validation of multiplexed SRM assays • Delivery format: Freeze dried in 96-well plates

SpikeTides™_L – heavy • Isotopically labeled, small scale, unpurified My group studies the proteomic com- proteotypic peptides with C-terminal heavy Arg “position of distinct chromatin domains, or Lys for development of SRM assays and relative quantitation of proteins using a single product the mechanisms that operate to main- • Delivery format: Freeze dried in 96-well plates tain the composition of histone modifi- cations and the associated proteins. For SpikeTides™_TQ – light and quantified precise and accurate identification and • Quantified, small scale, unlabeled proteotypic peptides. Each peptide carries a Quanti-Tag that quantification of histone peptides that will be cleaved by trypsin digestion • Delivery format: Freeze dried in 96-tube racks carry multiple post-translational modifi- (5 aliquots per peptide)

cations directly from biological samples & Pools Libraries Peptide JPT's SpikeTides™_TQL peptide standards SpikeTides™_TQL – heavy and quantified proved to be of excellent value for our • Quantified and heavily labeled, small scale, proteo­ typic peptides. Each peptide carries a Quanti-Tag research in various projects. that will be cleaved by trypsin digestion A. Imhof, Adolf-Butenandt Institute, University” of Munich, • Delivery format: Freeze dried in 96-tube racks (5 aliquots per peptide) Germany

Purity* QA / QC Scale* Delivery Delivery Format

Freeze-dried in 96 - or SpikeTides™ – light Unpurified 5 % LC-MS 50 nmol 3 weeks 384 -well plates

Freeze-dried in 96 - or SpikeTides™_L – heavy Unpurified 5 % LC-MS 10 nmol 3 weeks 384 -well plates

SpikeTides™_TQ – light Unpurified/ 5 x 1 nmol Freeze-dried in 100 % LC-MS 5 weeks and quantified Purified (target peptide) 96 -tube racks

SpikeTides™_TQL – Unpurified/ 5 x 1 nmol Freeze-dried in 100 % LC-MS 5 weeks heavy and quantified Purified (target peptide) 96 -tube racks

Maxi SpikeTides™_QL_ 100 % LC-MS 10 x 1nmol Freeze-dried in > 95 % 5 weeks AAA & AAA (target peptide) 96 -tube racks

* Please inquire for higher purity or larger amounts

17 pt id es Pe es om vic st r Se Cu

SpikeMix™ Peptide Pools & Sets

Our inexpensive stable isotope-labeled peptide pools and sets for use in mass spectrometry-based proteomics feature large numbers of heavy peptides, e.g., for cytokines, peptide hormones and tumor associated antigens. All heavy peptides are stable isotope-labeled using heavy arginine (U-13C6; U-15N4) or lysine (U-13C6; U-15N2).

Applications Selected References • Biomarker discovery and validation > “Quantitative Proteomics of Bronchoalveolar • Mass spectrometry based assays (SISCAPA, Lavage Fluid in Idiopathic Pulmonary Fibrosis” MRM, etc.) Foster et al., J of Proteome Research (2015) • Quantitation of immunomodulaters • Standardization of mass spectrometry-based > “Quantitative Variability of 342 Plasma Proteins in proteomics assays a Human Twin Population” Liu et al., Mol Syst Biol. (2015)

Benefits > “High Density and Ligand Affinity Confer • Quantitation of multiple protein targets from Ultrasensitive Signal Detection by a Guanylyl a single sample Cyclase Chemoreceptor” • Lowest prices for SIL peptides and quantified Pichlo et al., J Cell Biol. (2014) peptides • Multiplexed analysis of disease status and therapeutic success Peptide Libraries & Pools Libraries Peptide

 Select your SpikeMix™ & SpikeTides™ Set

Customized Non-Quantified JPT offers stable isotope- ABRF (cross-species standard) Absolutely labeled peptides tailored to CEF (ext.) Cytokines (human) Quantified your specifications. Alkylation Cytokines (12 further species) Kinase Activation Loops Histone H3 and post-translational modi- Peptide Hormones Metabolic fications are available as Tumor Associated Antigens Enzymes well as absolute quanti- tation. Wnt Signaling Pathway

A full up-to-date list can be found on: www.shop.jpt.com

As Director of the Protein Profiling at Yale Keck Biotechnology Resource Facility, “I coordinated a collaboration between the Association of Biomolecular Resource Facilities (ABRF) standard proteomic research group (sPRG) and JPT Peptide Tech- nologies to develop the ABRF cross-species SpikeMix™ Peptide Pool. The joint devel- opment turned out to be an extraordinarily effective endeavor and the resulting product was qualified in more than 52 proteomics labs around the globe. I was impressed by JPT's scientific and technological capabilities as well as their enthusi- asm to drive the project forward. C. M. Colangelo, Protein Profiling at Keck Biotechnology” Resource Facility, Yale University, USA

18 pt id es Pe es om vic st r Se Cu

BioTides™ Small Scale Biotinylated Peptides

BioTides™ are designed for your binding assays using streptavidin coated beads, membranes, glass slides or ELISA plates. BioTides™ are synthesized by JPT’s high- throughput synthesis method SPOT and represent the most economic source of biotinylated peptides.

Applications Product Specifications • Identification and optimization of kinase-, phos- • Amount of 50- 200 nmol per peptide phatase-, acetyltransferase- and histone deacety- • Peptide length: 6- 20mers lase-substrates via standard screening systems • N-terminally biotinylated via a hydrophilic flexible (AlphaScreen, FlashPlates, SPA-Beads etc.) linker, ensuring proper presentation of peptides • Mapping of protein/protein interaction sites (ELISA- • Unpurified but capped after each synthesis step like assays, precipitation of interacting proteins) for removal of deletion and truncation sequences • Production of peptide microarrays during re-immobilization to streptavidine matrices • Loading of columns for affinity chromatography • Incorporation of non-standard amino acids and other modifications possible Benefits • Highly parallel synthesis approach Selected References • Turnaround: > 10 000 peptides/week > “Epitope Mapping via Selection of anti-FVIII antibody- • Ready-to-use freeze dried peptides in 96-well Specific Phage-presented Peptide Ligands That microtiter plates Mimic the Antibody Binding Sites” • Low cost source for small scale biotinylated Kahle et al., Thromb Haemost (2015) & Pools Libraries Peptide peptides > “Evaluation of Viral Peptide Targeting to Porcine Sialoadhesin Using a Porcine Reproductive and Respiratory Syndrome Virus Vaccination-Challenge Model” Ooms et al., Virus Research (2013)

> “Human IgE Against the Major Allergen Bet v 1 – Defining an Epitope with Limited Cross-Reactivity Between Different PR-10 Family Protein” Levin et al., Clinical & Experimental Allergy (2013)

Immobilization of BioTides™ for binding assays.

load beads immobilize onto for affinity microtiter plates purifications

add enzyme print microarray

19 pt id es Pe es om vic st r Se Cu Peptide Arrays & Peptide ELISA

JPT uses its proprietary PepStar™, SPOTS™ and Peptide ELISA technologies for the validated production of peptide arrays, microarrays and ELISA. Peptides are immo­ bilized onto surfaces such as cellulose membranes or glass slides. They can represent proteins or a whole proteome as well as specific peptide sequences. Each microarray batch passes rigorous quality control ensuring high batch-to-batch reproducibility.

Benefits of Peptide Arrays [...] To map the epitopes of our newly • Chemoselective and directed immobilization “generated specific anti-rat TAAR1 anti- leads to proper presentation of binding sites • Synthetic peptides have high-batch-to-batch bodies we used JPT's PepStar™ Peptide reproducibility • Post-translational modifications or other modi­ Microarrays. The peptide microarrays fications possible greatly contributed to our successful and recently published study. We were very satisified with the exceptional product and service delivered by JPT Peptide Tech­nologies as well as their scientific Customer Support which was always at our disposal. S. Obermüller, F.Hoffmann” – La Roche Ltd., Roche Pharma Research and Early Development, Basel, Switzerland Peptide ArraysPeptide Elisa & Peptide

JPT’s Array Platform Peptide Origin Assay Type

Immune Monitoring , Overlapping peptide libraries, epitope collections, Seromarker Discovery, Antibody PepStar™ or RepliTope™ substitution or truncation libraries, alanine scans Signature Profiling, Epitope Mapping & Optimization

Overlapping peptide scans through antigens, Epitope Mapping, Validation PepSpots™ alanine-scans, substitutional or truncation analy- and Optimization ses of identified epitopes

Seromarker Discovery/Immune ULTRA peptide libraires with high coverage of PepStar™ ULTRA Monitoring of targets with sequence diversity, e.g. for HIV, cancer sequence diversity

PepStar™ Multiwell Selected Peptides from antigens Selective Antigen Profiling Microarray

Immune Profiling, Protein- Peptide ELISA Selected Peptides Protein Interaction Studies

Enzyme Substrate Peptide substrates derived from annotated sub- Enzyme Profiling Microarrays strate proteins

Histone Code Peptide Huge library of histone peptides with all potential Protein-Histone Interaction Microarray post-translational modifications Studies

Selection of JPT's array platforms and their applications.

20 pt id es Pe es om vic st r Se Cu

Microarray & ELISA Assay Service

JPT offers comprehensive incubation and analysis services using its peptide microarray platforms PepStar™ and RepliTope™ or Peptide ELISA. Save time for assay set-up and optimization and take advantage of our experience in data evaluation.

Applications Send us a short outline of your • Seromarker Profiling project and we will: • Receptor-ligand interaction studies • Suggest the appropriate array platform to be used • Antibody epitope mapping • Provide bioinformatic support for peptide and • Mimotope identification and optimization microarray design • Enzyme substrate identification and optimization • Provide project proposal and quotation • Synthesize peptides and generate peptide microarrays Benefits • Incubate microarrays with your sample and • Our proprietary peptide microarray platforms perform control experiments • Well established and automated assay procedures • Evaluate and interpret data • Sample handling and profiling regulated by • Provide comprehensive and confidential report DIN ISO 9001:2015 and GCLP • Strong bioinformatic support for array design and data interpretation

[...] JPT's PepStar™ Peptide Microarray platform as well as its full profiling service

“and data interpretation capabilities have been a reliable and robust approach to ArraysPeptide Elisa & Peptide elucidate the molecular details of these protein-protein interactions. J. Schultz, Carolus Therapeutics, Inc., San Diego, USA ”

High Content Peptide Microarray Large numbers of peptides tested using > 5000 peptides high content peptide microarrays. ~ 100 samples Library Content Hits are con rmed by selective tests with Multiwell Peptide Microarray thousands of samples applying multiwell ~200 peptides peptide microarrays. ~1000 samples

Validation by exible and robust Peptide ELISA Peptide ELISA. Results can be trans- exible design Sample Throughput ferred towards diagnostic assays.

21 pt id es Pe es om vic st r Se Cu

PepStar™ Customized Peptide Microarrays

With our PepStar™ Peptide Microarray platform we produce microarrays that combine several advantages over other microarrays. We utilize chemoselective coupling to generate microarrays displaying directed and covalently attached peptides that are purified in the process. Multiple copies of each peptide microarray are prepared with flexible layouts at unmatched economy.

Applications Selected References • Incubation with proteins, patient samples, > “ Traceamine-associated Receptor1 Activation Silences cell lysates, enzymes GSK3β Signaling of TAAR1 and D2R Heteromers” • Epitope mapping and optimization Harmeier et al., European • Antibody signature profiling Neuropsychopharmacology (2015) • Seromarker profiling • Immune monitoring > “ High-Throughput Microarray Incubations Using • Protein-protein interactions Multi-Well Chambers” Zerweck et al., Methods Mol Biol. (2015)

Benefits > “ Protective Efficacy of Adenovirus-protein Vaccines • Patented synthesis of peptides warrants high Against SIV Challenges in Rhesus Monkeys” batch-to-batch reproducibility Barouch et al., Science (2015) • Directed and chemoselective immobilization ensures availability of binding sites > “ Relationships Between T Cell and IgE/IgG4 Epitopes • Provision of thousands of identical microarrays of the Anisakis Simplex Major Allergen Ani s 1” • Low consumption of patient materials and Alonso et al., Clin Exp Allergy. (2015) proteins • High shelf stability • High assay sensitivity Peptide ArraysPeptide Elisa & Peptide

The PepStar™ Microarray layout depends on the num­ber of peptides and can be adjusted to your needs.

Left: High density microarray with 3 subarrays. Right: Multiwell Microarray with 21 subarrays (3 copies each) that can be incubated separatedly with different samples using a multiwell array chamber. PTPT PTPT PTPT

22 pt id es Pe es om vic st r Se Cu

RepliTope™ Catalog Peptide Microarrays

RepliTopes™ combine all the advantages of PepStar™ Microarrays with the availability of a catalog product. We selected many common antigens from infectious pathogens and cancer types. The RepliTope™ Antigen Collections are high density peptide micro­ arrays displaying large collections of antigens from, or even the whole proteome of a particular virus or bacterium.

Applications Selected References • Antibody epitope mapping and optimization > “ Antibodies to Influenza Nucleoprotein Cross-react • Antibody signature profiling with Human Hypocretin Receptor 2” • Seromarker discovery Ahmed et al., Science Translational Medicine (2015) • Immune monitoring • Protein-protein interactions > “ Serum Reactome Induced by Bordetella Pertussis Infection and Pertussis Vaccines: Qualitative Differences in Serum Antibody Recognition Patterns Benefits Revealed by Peptide Microarray Analysis” • Premade microarrays available within days Valentini et al., BMC Immunol. (2015) • RepliTopes™ display peptide scans through antigens or whole proteomes > “ H1N1 Viral Proteome Peptide Microarray Predicts • Each peptide is presented 2-4 times on each Individuals at Risk for H1N1 Infection and Segregates microarray to ensure reproducibility of results Infection Versus Pandemrix® -Vaccination” • Economical access to many identical peptide Aditya et al., Immunology (2015) microarrays

Selection of available RepliTopes™ Peptide ArraysPeptide Elisa & Peptide Tumor Associated Antigens Infectious Diseases Antigen Collections

Breast/Prostate Adenovirus HIV ULTRA • Mammaglobin A • Hexon and penton proteins • Gag p17 and p24, tat, nef and env, • NY-ESO-1 immunogenic regions for frequent • PSA ... BKV clades (A,B,C,D,G, CRF1,CRF2). • Capsid proteins (VP1, VP2, VP3) Coverage for ENV 57%, GAG 72%, Epithelia • Large and small T antigens NEF 62% and TAT 46%. • CEA • Claudin-6 ... EBV HBV ULTRA • EBNA (1, 2, 3a, 3b, 3c, LP) • Covers 255 proteins of 53 annotated Melanoma • LMP1 and LMP2 ... proteomes of HBV. Non-redundant • MAGEA1, A3 and A4 sequences from genes P, S, X, C for • Melan-A/MART-1 HCMVA 14 genotypes A1, A2, A3, B, B/C, B1, • Prame/OIP4 ... • IE-1, IE-2, pp65, B2, C, D, E, F1, F2, G and H. • UL28, UL32, UL40 ... Vaccinia virus M. tuberculosis ULTRA • MVA018L (Host range p. 2) Influenza A • 40 antigens of MTB reference strain • MVA093L (p53) ... • HA, MP1 and NC H37Rv supplemented by 354 ho­- from different strains mol­ogous antigens found in other Wilms tumor1 M. tuberculosis strains. 17 different • WT33 RSV MTB strains are represented by 6388 • Protein F, NC protein N peptides. Miscellaneous • Cyclin B1 Miscellaneous • Histone H1.2 and H4 • HBV (Large envelope protein) • P53_human ... • HHV6 (U54) • Yellow fever (NS24B) ...

A full up-to-date list can be found on: www.shop.jpt.com

23 pt id es Pe es om vic st r Se Cu

PepSpots™ Peptide Arrays on Membranes

PepSpots™ peptides are synthesized directly on cellulose membranes by SPOT tech­nology. The resulting PepSpots™ Peptide Arrays combine a reliable assay, easy experimental procedure (like ELISA), inexpensive equipment needs and a highly flexible array. Different array format are possible as well as post-translational and other peptide modifications. PepSpots™ are the method of choice for fast and reli­ able antibody epitope mapping.

Applications Selected References • Antibody epitope mapping > “ Differential and Concordant Roles for PARP1 and • Functional characterization of mapped epitopes Poly (ADP-ribose) in Regulating WRN and RECQL5 • Optimization of epitopes Activities” • Characterization of protein-protein contact sites Khadka et al., Mol Cell Biol. (2015)

> “ Itch WW Domains Inhibit its E3 Ubiquitin Ligase Benefits Activity by Blocking E2-E3 Transthiolation” • Peptides attached via a flexible linker Riling et al., J Biol Chem. (2015) • Membrane for direct use • Readout via chemiluminescence > “ Structural Differences of Amyloid-β fibrils Revealed • Hydrophilic cellulose membranes minimize by Antibodies From Phage Display” unspecific interactions Droste et al., BMC Biotechnol. (2015) • Detection of low affinity interactions • Easy standard protocols

Peptide ArraysPeptide Elisa & Peptide [...] we are collaborating with JPT for many years and are very satisfied with the rela- “tionship which led to several well received publications. Especially, their unique array technology PepSpots™ helped us to enhance our knowledge [...]. J. Schymkowitz, Vrije Universiteit Brussel, Belgium ”

Left: Your PepSpots™ package includes: PepSpots™ membrane, data CD and application protocol.

Right: Customized Peptide ELISA plates are available in different formats for various applications.

24 pt id es Pe es om vic st r Se Cu

Peptide ELISA

Peptide ELISA (Enzyme-linked immunosorbent assay) enables analysis and screening on amino acid sequence level. For example, mapping of epitopes or definition of protein interaction sites, thus providing much more information than conventional ELISA. We offer custom peptide ELISA plates with optional incubation and assay service and an off-the-shelf Histone Peptide ELISA for screening of PTM-specific anti-­­­ bodies or enzymes.

Peptide ELISA specifications Applications for Peptide ELISA • Discovery Grade: • Antibody epitope mapping Unpurified peptides but truncated sequences are • Immune profiling removed during immobilization • Determination of antibody titers • Validation Grade: • Analysis of protein-protein interactions Custom Peptides with full HPLC-MS analysis and • Analysis of enzymatic reactions guaranteed purity • Validation of microarray results

Selected References > “ Patients with Early Inflammatory Arthritis Who are > “ Evaluating the Efficacy of Aluminium Phosphate Anti-CCP Antibody Positive have Antibodies Against Formulated L2 Based HPV Vaccine” Acetylated and Carbamylated Vimentin Peptides” Lakshmikanth et al., Asian Journal of Juarez et al., Rheumatology (2015) Pharmaceutical and Clinical Research (2015)

> “ Restrictive IgG Antibody Response Against Mutated > “ Identification of Novel Antiacetylated Vimentin Citrullinated Vimentin Predicts Response to Antibodies in Patients with Early Inflammatory

Rituximab in Patients with Rheumatoid Arthritis” Arthritis” ArraysPeptide Elisa & Peptide Lindenberg et al., Arthritis Research & Therapy Juarez et al., Ann Rheum Dis (2015) (2015)

25 We take pride in our competent service and swift response. Please do not hesitate to contact us for further information. We also very much welcome your feedback and comments.

JPT Peptide Technologies www.jpt.com | [email protected]

Contact Volmerstraße 5 USA/Canada T +49-30-6392-7878 12489 Berlin T 1-888-578-2660

F +49-30-6392-7888 Germany F 1-888-578-2666 2020 November Issue Date: